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Abstract
We investigated the effects of agents acting at histamine receptors on both, spontaneous release of ACh from the basolateral
amygdala (BLA) of freely moving rats, and fear conditioning. Extensive evidence suggests that the effects of histamine on
cognition might be explained by the modulation of cholinergic systems. Using the microdialysis technique in freely moving rats,
we demonstrated that perfusion of the BLA with histaminergic compounds modulates the spontaneous release of ACh. The
addition of 100 mM KCl to the perfusion medium strongly stimulated ACh release, whereas, 0.5 mM tetrodotoxin (TTX) inhibited
spontaneous ACh release by more than 50%. Histaminergic H3 antagonists (ciproxifan, clobenpropit and thioperamide), directly
administered to the BLA, decreased ACh spontaneous release, an effect fully antagonized by the simultaneous perfusion of the
BLA with cimetidine, an H2 antagonist. Local administration of cimetidine alone increased ACh spontaneous release slightly, but
signi®cantly. Conversely, the administration of H1 antagonists failed to alter ACh spontaneous release. Rats receiving intra-BLA,
bilateral injections of the H3 antagonists at doses similar to those inhibiting ACh spontaneous release, immediately after
contextual fear conditioning, showed memory consolidation impairment of contextual fear conditioning. Post-training, bilateral
injections of 50 mg scopolamine also had an adverse effect on memory retention. These observations provide the ®rst evidence
that histamine receptors are involved in the modulation of cholinergic tone in the amygdala and in the consolidation of fear
conditioning.
Introduction
Considerable evidence indicates that the basolateral nuclei of the
amygdala (BLA) are implicated in memory of adverse events in a
wide variety of learning situations (PitkaÊnen et al., 1997; LeDoux,
2000; McGaugh, 2000; Nader et al. 2000). For example, the BLA
appears to be involved in the consolidation of both contextual and
auditory fear (Sacchetti et al., 1999). Moreover, pharmacological
manipulation of the BLA, with drugs in¯uencing GABAergic, opioid
or cholinergic systems, affects memory consolidation for adverse
events (Helmstetter & Bellgowan, 1994; McGaugh et al., 1996;
Wilensky et al. 2000). In particular, muscarinic receptor activation
within the amygdala appears to be critical in the memory for adverse
stimuli (McGaugh et al., 1996). Indeed, intra-amygdala post-training
injection of oxotremorine, a muscarinic agonist, enhanced memory in
an inhibitory avoidance task (Introini-Collison et al., 1996) and in
contextual fear conditioning (Vazdarjanova & McGaugh, 1999).
Conversely, intra-amygdala post-training injections of atropine, a
muscarinic antagonist, prevented memory enhancement produced by
systemic administration of muscarinic agonists (Dalmaz et al., 1993;
Introini-Collison et al., 1996). Thus, neurotransmitters that affect
BLA cholinergic activity might also in¯uence memory consolidation,
as is the case for the cholinergic systems in the cortex and in the
hippocampus (Blandina et al., 1996; Passani & Blandina, 1998;
Pepeu & Blandina, 1998).
The BLA is innervated by cholinergic ®bers that originate in the
nucleus basalis magnocellularis (Mesulam et al., 1983) and receives
the major input from cortical and subcortical sensory areas (Davis
et al., 1994). In addition, it receives histaminergic projections from
the hypothalamus (Inagaki et al., 1988; Panula et al., 1989).
Histaminergic modulation of basal forebrain cholinergic neurons
has been demonstrated and the mechanisms included both inter-
actions on target cell bodies (Mochizuki et al., 1991; Katheb et al.,
1995; Gorelova & Reiner, 1996; Cecchi et al. 2001) and also
modulation of ACh release from nerve endings (Arrang et al., 1995;
Clapham & Kilpatrick, 1992). For example, locally applied histamine
decreased the cholinergic tone in the cortex of freely moving rats by
activating H3 receptors (Blandina et al., 1996), through a mechanism
which involved GABAergic interneurons (Giorgetti et al. 2000). This
interaction may have functional relevance, as systemic administration
of H3 receptor agonists impaired rat performance in cognitive tasks at
the same doses that reduced ACh release from freely moving rat
cortex (Blandina et al., 1996). This ®nding is in agreement with the
observations that reduced availability of ACh in the synaptic cleft
may result in cognitive de®cits (Quirion et al., 1995). It is also
consistent with reports of H3 receptor antagonists' procognitive
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effects in normal (Prast et al., 1996; Ligneau et al., 1998) and
scopolamine-impaired rats (Giovannini et al., 1999), as well as in
senescence-accelerated mice (Meguro et al., 1992). Indeed, there is
much evidence suggesting that the effects of histamine on cognition
might be explained by the modulation of cholinergic systems (Passani
& Blandina, 1998; Nakazato et al. 2000; Passani et al. 2000a). The
current study investigates the neuromodulatory effect of brain
histamine on ACh release from the BLA of freely moving animals,
and on contextual fear conditioning. Some of these results have been
reported in abstract form (Passani et al. 2000b).
Materials and methods
Animal housing
Male Wistar rats (250±280 g) were housed in groups of three in a
temperature-controlled room (20±24 °C), allowed free access to food
and water, and kept on a 12-h light : 12-h dark cycle. All the
experiments were performed in strict compliance with the EEC
recommendations for the care and use of laboratory animals (86/609/
CEE), and were approved by the Animal Care Committee of the
`Dipartimento di Farmacologia Preclinica e Clinica' of the
`UniversitaÂ di Firenze'.
Surgery and microdialysis
The rats were anaesthetized with chloral hydrate (400 mg/kg i. p.)
and placed in a stereotaxic frame (Stellar, Stoelting Co., Wood Dale,
IL). Each rat was implanted with a guide cannula (Metalant, Sweden)
according to the following coordinates from bregma (Paxinos &
Watson, 1982): AP, ±2.8 mm, L, ±4.9 and H, 3.8. A surgical screw
served as an anchor and the guide cannula was ®xed to the skull with
acrylic dental cement. After surgical manipulations, rats were
replaced in their cages (one rat per cage) to recover from surgery.
Each rat was used for a single experiment. The microdialysis
experiments were performed 24 h after surgery. The stylet was
removed from the guide cannula and a microdialysis probe (1.5 mm
dialysing membrane molecular weight cut-off at 6000 Da; Metalant,
Sweden) was lowered into the BLA. The tip of the probe extended
4.5 mm beyond the tip of the guide cannula. The microdialysis probe
was perfused at a rate of 1.35 mL/min using a microperfusion pump
(Carnegie Medicine, Sweden; mod. CMA/100) with Ringer solution
(in mM: NaCl, 147; CaCl2, 1.2 and KCl, 4.0 at pH 7.0). To recover
detectable dialysate concentrations of ACh, a cholinesterase inhibitor
(0.1 mM neostigmine bromide) was added to the medium perfusing
the BLA. Solutes with molecular weight lower than 6000 Da were
allowed to cross the dialysis membrane according to their concen-
tration gradient. Hence, both suitable endogenous molecules and
exogenous compounds could feasibly be collected and administered,
respectively. Drugs, alone or in combination, were added to the BLA
perfusing medium. After an equilibration period of 2 h, fractions
were collected at 20-min intervals. The BLA was perfused with
control medium in the ®rst four fractions to measure ACh
spontaneous release and drugs were then added to the medium.
Histology
Accurate placement of microdialysis membranes was veri®ed
histologically. The rats were killed by an overdose of chloral hydrate,
the brains were removed and stored in 10% formaline for 10 days.
Forty-mM sections were sliced on a cryostat, mounted on gelatin-
coated slides and then stained with cresyl violet for light microscopy
observation. Data from rats in which the membranes were not
correctly positioned were discarded.
Assay of ACh
Acetylcholine was determined by HPLC-electrochemical detection as
described previously (Giorgetti et al. 2000). Brie¯y, ACh was
separated on the cation exchange column. ACh was hydrolysed by
acetylcholinesterase to form acetate and choline in the post-column
enzyme reactor, then choline was oxidized by choline oxidase to
produce betaine and hydrogen peroxide. Hydrogen peroxide was
detected by a platinum electrode with the potential set at 0.5 V. Peaks
were identi®ed by comparison of their retention times with those of
the standards.
Quanti®cation of ACh
The levels of ACh in the perfusate were calculated by comparison of
sample peak heights with external standard peak height and expressed
as pmol/20 min. Calibration curves for ACh were constructed by
plotting the heights of peaks against the concentrations. Regression
lines were then calculated and determination of unknown samples
was carried out by the method of inverse prediction. Acetylcholine
spontaneous release was calculated for each experiment by averaging
the mean of the four 20-min samples of perfusate collected before
drug treatment. Acetylcholine release was expressed as a percent of
its spontaneous release value. The in vitro recovery of ACh from the
dialysis membrane was about 60% at room temperature. Values
reported here were not corrected for recovery.
Statistical analysis
All values are expressed as means 6 SEM and the number of rats
used in each experiments is also indicated. The presence of signi®cant
treatment effects was ®rst determined by a one-way or a two-way
analysis of variance (ANOVA) followed by Bonferroni's or Scheffe's
and Neuman±Keuls tests, as appropriate. For all statistical tests,
P < 0.05 was considered signi®cant. Scheffe's procedure for post-hoc
comparisons performed all possible comparisons of the means. For
clarity purposes and for its biological relevance we reported in ®gures
and ®gure legends only the signi®cant differences vs. the last sample
before drug treatment. Statistical analysis was performed using
StatView (Abacus Concepts, Inc., Berkeley, CA) and GraphPad
Prism (GraphPad Software, Inc., San Diego, CA).
Behavioural experiments
Experiments were performed on 70-day-old male albino Wistar rats
(average body-weight 290 g). The animals were individually housed
in stainless steel cages in a room with a natural light : dark cycle
(windows) and constant temperature of 20 6 1 °C. The rats had free
access to food and water throughout the experiments.
Apparatus
A basic Skinner box module (Modular Operant Cage, Coulbourn
Instruments Inc.) was used to induce contextual conditioned freezing
as in previous experiments (Sacchetti et al., 1999). Box dimensions
were 29 3 31 3 26 cm. The top and the two opposite sides were
made of aluminium panels. The other two sides were made of
transparent plastic. The ¯oor was made of stainless steel rods
connected to a shock delivery apparatus (Grid Floor Shocker, model
E13-08, Coulbourn Instruments Inc.). The apparatus was connected to
a stimulus programming device (Scatola di comando Arco 2340,
Ugo Basile, Italy) to predetermine the number and duration of the
electric shocks and the duration of the intervals between them. The
apparatus was placed in an acoustically insulated room kept at a
constant temperature of 20 6 1 °C. Illumination inside the room
was 60 lux.
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Contextual fear conditioning procedure
The rat was gently taken manually from the home cage, placed in a
bucket and carried from the housing room to the soundproof room.
Once there, it was placed inside the conditioning apparatus. The rat
was left undisturbed for 3 min. After this time seven 1- s, 1-mA
electric footshocks were administered at 30 s intervals. Two minutes
after the end of the stimulation, the rats were removed, thus spending
a total time of 8 min inside the conditioning apparatus.
Conditioned freezing measurements
Freezing duration was measured 72 h after conditioning by an
experimenter blind to the animal's treatment. To measure freezing,
the animals were again placed inside the conditioning apparatus and
left for 3 min, during which they did not receive electrical
stimulation. After that time, they were brought back to the home
cage. Each rat's behaviour was recorded by means of a closed circuit
television system. Freezing was de®ned as complete absence of
somatic mobility, with the exception of respiratory movements.
Freezing time was measured with a stop-watch. All behavioural
testings were performed between 10.00 am and 12.00 pm.
Surgery and drug administration
Injections into the BLA were performed immediately after the
training. Brie¯y, drugs dissolved in physiological saline were injected
under general anaesthesia (ketamine, 100 mg/kg i.p.) into the BLA of
rats restrained in a stereotaxic apparatus. The same coordinates were
used as for the implantation of the microdialysis probes [according to
Paxinos & Watson (1982)]. The tip of the needle was placed 8.7 mm
ventral to bregma. The injection needle (outside diameter, 0.3 mm)
was connected with a short piece of polyethylene tubing to a
Hamilton syringe that was ®xed to an electrode holder. Solutions
(0.5 mL per side) were injected over a 1±2-min period and the needle
was left in place for another min before withholding it. Control
groups received bilateral injections of saline.
Histology
At the end of the experiments, rats were deeply anaesthetized and
perfused intracardially with 5% paraformaldehyde. Brain sections
were cut with a freezing microtome and Nissl-stained to verify
injection sites. Animals in which histological evidence was not
adequate were discarded.
Data analysis
For each session, data were expressed as seconds spent freezing
within the 3 min of testing. One-way ANOVA and Neuman±Keuls post
hoc test were used. For all statistical tests, P < 0.05 was considered
signi®cant.
Chemicals
The substances used in this study included cimetidine, neostigmine
bromide, thioperamide maleate, triprolidine dihydrochloride (RBI,
Natick, MA, USA); tetrodotoxin (Sigma), scopolamine hydrobromide
(Sigma), clobenpropit dihydrobromide was provided by Drs R. Leurs
and H. Timmerman and ciproxifan was provided by Dr W. Schunack.
All other reagents and solvents were of HPLC grade or the highest
grade available (Sigma, UK).
Results
Three examples of the medial, ventral and lateral-most locations of
the dialysing membrane within the BLA are shown in Fig. 1A. A
photomicrograph of a representative probe placement in the BLA is
illustrated in Fig. 1B.
Spontaneous release of ACh from the BLA of freely moving
rats and its modulation by potassium and TTX
Twenty-four hours after implantation of the dialysis probe, the
microdialysis membrane was perfused with Ringer solution contain-
ing 0.1 mM neostigmine. After 120 min of equilibration, the rat BLA
spontaneously released ACh at a stable rate, 0.32 6 0.07 pmol/
20 min (n = 62). Spontaneous ACh release was calculated for each
experiment by averaging the mean of the four 20-min samples of
perfusate collected before drug treatment and did not decrease
signi®cantly with time. The introduction of 0.1 mM neostigmine, a
cholinesterase inhibitor, into the perfusing medium was necessary to
recover detectable dialysate concentrations of ACh. This concentra-
FIG. 1. Placement of dialysing membranes within the BLA. (A) Schematic drawing illustrating the placement of three probes representing the most lateral,
medial and ventral positions. The length of the bar corresponds to the extent of the dialysing membrane. The number indicates the relative position of the
coronal section posterior to bregma according to Paxinos & Watson (1982). (B) Photomicrograph of the probe tip location. CE, central nucleus; BLA,
basolateral complex; L, lateral nucleus; Pir Cx, piriform cortex. Scale bar, 0.5 mm.
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tion of neostigmine was chosen on the basis of pilot data showing that
0.05 mM neostigmine was insuf®cient to produce consistently detect-
able dialysate concentrations of ACh, whereas 0.5 mM neostigmine
was less effective than 0.1 mM, probably due to the activation of
negative feedback mechanisms (Marshall & Wurtman, 1993).
Depolarization, induced by perfusing the BLA with a medium
containing 100 mM potassium for 20 min, strongly stimulated the
release of ACh, producing a maximal increase of 335 6 62%
(Fig. 2). The maximal effect occurred in the 20-min fraction collected
during perfusion with 100 mM potassium, and the level of the
spontaneous release of ACh was restored during the subsequent
perfusion with control medium. During the potassium pulse, the rats
did not show any abnormal behaviour. The spontaneous release in
this set of experiments was 0.36 6 0.03 pmol/20 min (n = 5).
The infusion of 0.5 mM tetrodotoxin (TTX), a voltage-dependent
sodium-channel blocker, for 100 min into the amygdala through the
dialysis probe reduced spontaneous ACh release by more than 50%
(Fig. 3). Spontaneous release averaged 0.28 6 0.02 pmol/20 min
(n = 7). ACh release slowly returned to basal values upon washout
(Fig. 3). During TTX exposure the rats did not show any abnormal
behaviour.
Local administration of H3 receptor antagonists in the BLA
decreased spontaneous release of ACh
Thioperamide, a selective H3 receptor antagonist (Arrang et al.,
1987a), added to the BLA-perfusing medium for 40 min at a
concentration of 30 nM, signi®cantly modulated spontaneous ACh
release, thus causing a maximal decrease of 37 6 2% (Fig. 4). The
spontaneous release of ACh averaged 0.29 6 0.07 pmol/20 min
(n = 4). An identical perfusion with 300 nM thioperamide elicited a
53 6 7% maximal decrease in ACh release (Fig. 4). The spontaneous
release of ACh averaged 0.26 6 0.05 pmol/20 min (n = 4). The
maximal effect was always achieved in the 20-min fraction collected
after thioperamide was withdrawn from the perfusing medium.
Spontaneous ACh release level was restored after withdrawal of
thioperamide from BLA perfusion medium. The inhibition of ACh
release caused by perfusion with medium containing 30 nM
thioperamide was not signi®cantly different from that caused by
perfusion with 300 nM thioperamide-containing medium (Two-way
ANOVA and Bonferroni's test).
An identical BLA perfusion with 300 nM clobenpropit, another H3
receptor antagonist (VanderGoot et al., 1992), caused a 62 6 10%
maximal decrease of ACh spontaneous release (Fig. 5). Eventually,
ACh release was restored to control levels during subsequent
perfusion with control medium. The spontaneous release of ACh
averaged 0.28 6 0.05 pmol/20 min (n = 4). As with thioperamide,
there was a time delay between the onset of drug perfusion and the
achievement of the maximal drug effect, that occurred in the second
20-min fraction collected after clobenpropit was withdrawn from the
perfusing medium (Fig. 5).
FIG. 2. Spontaneous- and 100 mM KCl-evoked release of ACh from the
BLA of freely moving rats. Twenty-four h after implantation of the dialysis
®bre, ACh was measured in fractions collected every 20 min, beginning 2 h
after the onset of the perfusion. Spontaneous release of ACh was calculated
for each experiment by averaging the mean of the four, initially collected,
20-min samples of perfusate. At 80 min the perfusion medium was changed
from 4 to 100 mM KCl for 20 min. Isotonicity was maintained by reducing
NaCl concentration. Acetylcholine release was expressed as percentage of
its spontaneous release value. The mean spontaneous release was
0.36 6 0.03 pmol/20 min. The black bar shows the period of 100 mM KCl
application to the BLA. Shown are means 6 SEM of ®ve rats.
***P < 0.001 vs. the last sample before drug treatment (ANOVA and
Scheffe's test).
FIG. 3. In¯uence of TTX on spontaneous ACh release from the BLA of
freely moving rats. Twenty-four h after implantation of the dialysis ®bre,
ACh was measured in fractions collected every 20 min, beginning 2 h after
the onset of the perfusion. At 80 min, 0.5 mM TTX was added to the
perfusing medium and administered for 100 min. The control value for ACh
spontaneous release was calculated as in Fig. 2. and ACh release was
expressed as percentage of its spontaneous release value. The mean
spontaneous release averaged 0.28 6 0.02 pmol/20 min. The black bar
indicates the period of TTX application. Shown are means 6 SEM of seven
rats. ***P < 0.001, **P < 0.01 and *P < 0.05. Differences were signi®cant
vs. the last sample before drug treatment (ANOVA and Scheffe's test).
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A signi®cant decrease in spontaneous ACh release from the BLA
was also observed following the 40 min perfusion with medium
containing 50 nM ciproxifan, another potent and selective H3 receptor
antagonist (Ligneau et al., 1998). Ciproxifan elicited a 60 6 6%
maximal decrease of spontaneous ACh release with a time course
similar to that obtained with both thioperamide and clobenpropit
(Fig. 6). As for thioperamide and clobenpropit, the ciproxifan effect
was completely reversible (Fig. 6). The spontaneous release of ACh
was 0.6 6 0.2 pmol/20 min (n = 3).
H2 receptor antagonism increased the spontaneous release of
ACh and antagonized the inhibition produced by H3 receptor
antagonists
The effect of blocking H2 receptors on ACh spontaneous release was
tested by perfusing the BLA with 100 mM cimetidine, a selective H2
antagonist (Durant et al., 1977). After collecting four 20-min fractions,
cimetidine was perfused for 40 min (Fig. 7). Cimetidine produced a
small but signi®cant increase in spontaneous ACh release in the second
20-min fraction after the onset of BLA perfusion with this H2
antagonist (Fig. 7). ACh release was restored to control levels during
subsequent perfusion with control medium (Fig. 7). The spontaneous
ACh release averaged 0.3 6 0.03 pmol/20 min (n = 12).
Figures 8 and 9 show the time course of ACh release from the
BLA evoked by the local administration of thioperamide or
clobenpropit, respectively, in the presence of cimetidine. After
collection of four 20-min baseline samples, 100 mM cimetidine was
added to the perfusing medium for 40 min, and was then adminis-
tered in combination with either 300 nM thioperamide (Fig. 8) or
300 nM clobenpropit (Fig. 9) for an additional 40 min. Medium
containing 100 mM cimetidine was then restored for the following
40 min. Washout with control medium was carried out for the ®nal
four 20-min fractions. In the presence of cimetidine, the inhibitory
effect of thioperamide on ACh release was completely abolished
(Fig. 8). The data shown in Fig. 8 A were compared with those
presented in Fig. 4. There was a signi®cant effect of both concen-
tration±time interaction (F1,98 = 3.789, P < 0.0001) and drug treat-
ment (F1,13 = 2.723, P < 0.0001) (Two-way ANOVA). Both ninth and
tenth 20-min fractions shown in Fig. 8 were signi®cantly different
when compared to the corresponding 20-min fractions of Fig. 4
(P < 0.001, Bonferroni's test).
A similar effect was observed when clobenpropit was infused into
the BLA in the presence of cimetidine. Figure 9 shows that the
inhibitory effect of clobenpropit (300 nM) on ACh release was fully
counteracted by cimetidine (100 mM). The data shown in Fig. 9 were
compared with those presented in Fig. 5. There was a signi®cant
effect of both concentration±time interaction (F1,112 = 7.105,
P < 0.0001) and drug treatment (F1,13 = 2.582, P < 0.0001) (Two-
way ANOVA). Both ninth (P < 0.01, Bonferroni's test) and tenth
(P < 0.001, Bonferroni's test) 20-min fractions shown in Fig. 9 were
signi®cantly different when compared to the corresponding 20-min
fractions of Fig. 5. Spontaneous ACh release averaged
0.42 6 0.05 pmol/20min (n = 5) in the experiments with thioper-
amide and cimetidine, and 0.45 6 0.05 pmol/20 min (n = 6) in those
with clobenpropit and cimetidine.
FIG. 4. Time course of thioperamide-induced inhibition of spontaneous ACh
release from the BLA of freely moving rats. Acetylcholine was measured in
fractions collected every 20 min, beginning 2 h after the onset of the
perfusion. The control value for spontaneous ACh release was calculated as
in Fig. 2. and ACh release was expressed as percentage of its spontaneous
release value. Thioperamide (THIO, 30 and 300 nM) was administered
into the BLA through the dialysis probe at 120 min and stopped at 160 min.
The mean spontaneous release was 0.29 6 0.07 pmol/20 min in the
experiments with 30 nM thioperamide, and 0.26 6 0.05 pmol/20 min in
those with 300 nM thioperamide. The black bar indicates the period of
thioperamide application. Shown are means 6 SEM of four rats in each
group. §§, **P < 0.01 and §, *P < 0.05 vs. last sample before drug treatment
(ANOVA and Scheffe's test).
FIG. 5. Clobenpropit-induced inhibition of spontaneous ACh release from
the BLA of freely moving rats. Acetylcholine was measured in fractions
collected every 20 min, beginning 2 h after the onset of the perfusion. After
120 min, clobenpropit (CLOB, 300 nM) was administered through the
dialysing membrane for 40 min. Spontaneous ACh release was calculated
for each experiment by averaging the mean of the four 20-min samples of
perfusate collected before drug treatment. Acetylcholine release was
expressed as percentage of its spontaneous release value. The mean
spontaneous release averaged 0.28 6 0.05 pmol/20 min. The black bar
indicates the period of clobenpropit application. Shown are means 6 SEM
of four rats. ***P < 0.001 and *P < 0.05 vs. the last sample before drug
treatment (ANOVA and Scheffe's test).
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Effects of H1 receptor antagonism on spontaneous release of
ACh
Introduction of 300 nM triprolidine, an H1 receptor antagonist (Ison &
Casy, 1971), into the BLA perfusing medium had no signi®cant effect
on spontaneous ACh release. After collection of four 20-min baseline
samples (spontaneous release was 0.17 6 0.02 pmol/20 min; n = 3),
triprolidine was administered through the dialysis membrane for
40 min. Following the drug perfusion period, three 20-min control
samples were collected during washout. The changes in spontaneous
ACh release were always within the range of variability (less than
6 20%) observed between individual 20-min collection periods
during BLA perfusion with control medium (data not shown).
Memory for contextual fear conditioning was impaired by post-
training infusion of H3 receptor antagonists and scopolamine
in the BLA
In these experiments, we examined the effects of post-training
bilateral injections into the BLA of scopolamine, a muscarinic
antagonist, thioperamide or clobenpropit on contextual fear condi-
tioning. Figure 10 shows a representative location of the needle tips
of an operated animal. When either one or both cannulae were outside
the ranges outlined in Fig. 1, the animals were discarded. Each drug
was diluted in saline to permit the bilateral intra-BLA injection of a
constant volume (0.5 mL) to each rat. As 50 mg of scopolamine
injected into the rat amygdala impaired working memory in the
double-Y maze (Ingles et al., 1993), the same dose was used in this
study. On the other hand, the doses of thioperamide and clobenpropit
injected were based upon the results of the microdialysis experiments.
For example, 0.5 mL of a 300-nM solution of thioperamide corres-
ponded to a total amount of 44 pg, and a 0.5-mL of a 3-mM solution of
clobenpropit corresponded to 464 pg. During training, there were no
differences in the level of freezing between the control rats (to be
injected with saline) and those to be injected with drugs after training
(data not shown). Rats that received bilateral intra-BLA infusions of
the histaminergic compounds failed to show any modi®cation in their
behaviour (locomotor and exploratory activities, grooming, yawning
and rearing) during the three days between training and testing.
Analysis of variance on the freezing behaviour revealed a signi®cant
treatment effect (F7,67 = 5.419, P < 0.0001; Fig. 11). Neuman±Keuls
post hoc analysis showed that rats receiving 44 pg thioperamide
(n = 9), 4.4 pg thioperamide (n = 9), 464 pg clobenpropit (n = 9)
and 50 mg scopolamine (n = 8) spent signi®cantly less time freezing
than saline-injected controls (n = 11; P < 0.01 in all cases). There
were no signi®cant differences between animals treated with 0.44 pg
thioperamide (n = 9), 46.4 pg clobenpropit (n = 8) and 10 mg
scopolamine (n = 6) and controls.
Discussion
The results of the present study provide the ®rst evidence that intra-
BLA administration of histaminergic compounds alters the rate of
FIG. 6. Ciproxifan-induced inhibition of spontaneous ACh release from the
BLA of freely moving rats. Acetylcholine was measured in fractions
collected every 20 min, beginning 2 h after the onset of the perfusion. After
80 min, ciproxifan (CIPRO 50 nM) was added to the perfusing medium and
administered for 40 min. The control value for spontaneous ACh release
was calculated as in Fig. 2. and ACh release was expressed as percentage of
its spontaneous release value. The mean spontaneous release averaged
0.6 6 0.2 pmol/20 min. The black bar indicates the period of ciproxifan
application. Shown are means 6 SEM of three rats. *P < 0.05 vs. last
sample before drug treatment (ANOVA and Scheffe's test).
FIG. 7. Effect of cimetidine on spontaneous ACh release from the BLA of
freely moving rats. Acetylcholine was measured in fractions collected every
20 min, beginning 2 h after the onset of the perfusion. Cimetidine (CIM,
100 mM) was added to the perfusing medium after collecting four 20-min
fractions, and administered for the following 40 min as indicated by the bar.
The control value for spontaneous ACh release was calculated as in Fig. 2,
and ACh release was expressed as percentage of its spontaneous release
value. The mean spontaneous release averaged 0.3 6 0.03 pmol/20 min
(n = 12). The black bar indicates the period of cimetidine application.
Shown are means 6 SEM of twelve rats. *P < 0.05 vs. last sample before
drug treatment (ANOVA and Scheffe's test).
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spontaneous ACh release and impairs memory for contextual fear
conditioning. The BLA receives cholinergic innervation from the
nucleus basalis magnocellularis (NBM) (Mesulam et al., 1983;
Carlsen et al., 1985). Only sparse cholinergic cell bodies are found in
the anterior amygdala (Nitecka & Frotscher, 1989). The use of the
microdialysis technique was validated by perfusing the BLA with
100 mM KCl to increase BLA ACh extracellular levels. This
concentration of KCl may appear high, however, low potassium
recovery through the microdialysis membrane, and its rapid dilution
into the extracellular space after crossing the membrane necessitate
high concentrations in the perfusion medium (Westerink & DeVries,
1996). Moreover, administration of TTX decreased extracellular ACh
levels by about 50%, thus indicating the presence of spontaneous
impulse activity in NBM±BLA cholinergic neurons at rest.
The use of cholinesterase inhibitors may be criticized because they
may alter modulation of ACh release, as in the case of dopamine on
striatal ACh release (DeBoer & Abercrombie, 1996). However, the
amygdala, as well as the cortex (Herrera-Marschitz et al., 1990),
release much lower levels of ACh compared to the striatum, thus
requiring the presence of cholinesterase inhibitors in the perfusion
¯uid. It is noteworthy that concentrations of neostigmine up to 0.5 mM
failed to alter cortical ACh release patterns qualitatively in response
to behavioural activation (Himmelheber et al., 1998).
Inhibition of ACh release caused by thioperamide, clobenpropit or
ciproxifan appears to be mediated by H3 receptors localized in the
BLA. This release was inhibited by perfusion with medium contain-
ing 30 and 300 nM thioperamide or 300 nM clobenpropit, both
competitive antagonists at H3 receptors with pA2 values in cortical
slices of 8.96 (Arrang et al., 1987a) and 9.5 (Kathmann et al., 1993).
Another highly selective H3-antagonist, ciproxifan (Ligneau et al.,
1998) ± about 10 3 more potent than thioperamide ± at 50 nM,
caused a decrease in amplitude and time course of ACh release
similar to that produced by thioperamide or clobenpropit. The
involvement of H3 receptors is further demonstrated by the presence
of H3 receptor binding (Pollard et al., 1993) and with the distribution
of mRNA encoding for H3 receptors (Lovenberg et al., 1999) in the
BLA. H3 receptors, initially detected as presynaptic autoreceptors
inhibiting histamine release (Arrang et al., 1983; Arrang et al.,
1987b), were shown subsequently to act also as presynaptic
heteroreceptors in non-histamine-containing neurons (for a review,
see Hill et al., 1997). H3 receptors are G-protein-coupled receptors
that inhibit cAMP formation (Lovenberg et al., 1999). However, the
FIG. 8. Reversal by cimetidine of thioperamide induced inhibition of ACh
release from the BLA of freely moving rats. Acetylcholine was measured in
fractions collected every 20 min, beginning 2 h after the onset of the
perfusion. Spontaneous ACh release was calculated for each experiment by
averaging the mean of the four 20-min samples of perfusate collected
before drug treatment. Thioperamide (300 nM) was administered at 120 min
into the BLA through the dialysis probe for 40 min in the presence of
cimetidine (100 mM), that was added to amygdala-perfusing medium 40 min
before administration of thioperamide, and kept in the medium for 40
additional min after thioperamide was withdrawn. Acetylcholine release was
expressed as percentage of its spontaneous release value. Spontaneous ACh
release was 0.42 6 0.05. The black bars indicate the period of drug
applications. Each point represents the mean value 6 SEM of ®ve rats.
Statistical comparison was performed with the experiments shown in Fig. 4.
There was a signi®cant effect of concentration±time interaction (F1,98 =
3.789, P < 0.0001) and of drug treatment (F1,13 = 2.723, P < 0.0001) (Two-
way ANOVA). ***P < 0.001 vs. corresponding 20-min fractions shown in
Fig. 4. (Bonferroni's test).
FIG. 9. Reversal by cimetidine of clobenpropit induced inhibition of ACh
release from the BLA of freely moving rats. Acetylcholine was measured in
fractions collected every 20 min, beginning 2 h after the onset of the
perfusion. Spontaneous ACh release was calculated for each experiment by
averaging the mean of the four 20-min samples of perfusate collected
before drug treatment. Clobenpropit (300 nM) was administered at 120 min
into the BLA through the dialysis probe for 40 min in the presence of
cimetidine (100 mM), that was added to amygdala-perfusing medium 40 min
before administration of clobenpropit, and kept in the medium for 40
additional min after clobenpropit was withdrawn. Acetylcholine release was
expressed as percentage of its spontaneous release value. Spontaneous ACh
release was 0.45 6 0.05. The black bars indicate the period of drug
applications. Each bar represents the mean value 6 SEM of six rats.
Statistical comparison was performed with the experiments shown in Fig. 5.
There was a signi®cant effect of concentration±time interaction
(F1,112 = 7.105, P < 0.0001) and of drug treatment (F1,13 = 2.582,
P < 0.0001) (Two-way ANOVA). **P < 0.01 and ***P < 0.001 vs.
corresponding 20-min fractions shown in Fig. 5 (Bonferroni's test).
1528 B. Passani et al.
ã 2001 Federation of European Neuroscience Societies, European Journal of Neuroscience, 14, 1522±1532
identi®cation of isoforms with distinct CNS expression pro®les and
coupling to adenylylcyclase or MAP-kinase signalling pathways
(Drutel et al. 2001), adds more complexity to the understanding of
their functions. Pretreatment with cimetidine, at a concentration
suf®cient to fully block H2 receptors (Durant et al., 1977), completely
abolished the effect of thioperamide and clobenpropit. These
observations, together with the demonstration that, in the BLA H3-
receptor binding is strictly associated with the presence of
histaminergic ®bers (Anichtchik et al. 2000), suggest a role for
endogenous histamine in the control of BLA ACh release. The
inhibition elicited by H3-antagonists could be most simply explained
by a blockade of H3 autoreceptors, which is accompanied by an
increase in endogenous histamine release (Arrang et al., 1983).
Histamine, activating postsynaptic H2 receptors, might inhibit ACh
release. The BLA receives the most abundant histaminergic
innervation in the brain (Ben-Ari et al., 1977), and displays both
high H2-receptor binding and its gene transcripts (Vizuete et al.,
1997). The anatomical arrangement of H2 receptors in the amygdala
is unknown. Several hypotheses based on the intracellular cascade of
events brought about when activating H2 receptors can be proposed to
explain inhibition of ACh release. H2 receptors are positively coupled
with adenylylcyclase (Johnson, 1982) and reduce a calcium-activated
potassium current in the hippocampus, thus increasing the amplitude
of population spikes (Haas, 1984; Haas & Greene, 1986). However,
they also negatively modulate outward currents through phosphoryl-
ation of Kv3.2-containing potassium channels, hence lowering the
neuronal maximal ®ring frequency (Atzori et al. 2000). They also
elicite inhibitory postsynaptic potentials in supraoptic oxytocin-
neurons, presumably by opening chloride channels (Yang & Hatton,
1994). Therefore, H2 receptors might inhibit ACh release directly,
acting at BLA cholinergic terminals, or indirectly through activation
of inhibitory interneurons, largely present in the amygdala
(Kemppainen & PitkaÊnen, 2000). Interestingly, histamine inhibition
of amygdaloid kindled seizures (Ishizawa et al. 2000) and
histaminergic inhibition of cortical ACh release both involve
GABAergic transmission (Giorgetti et al., 1997).
Conversely, modulation of ACh release from the amygdala did not
involve H1 receptors, as perfusion with the H1-antagonist, triprolidine
at a concentration suf®cient to fully occupy H1 receptors (Ison &
Casy, 1971), failed to modify ACh release.
In addition to preventing H3-antagonist-elicited inhibition, adminis-
tration of cimetidine alone increased ACh spontaneous release, thus
indicating the occurrence of a histaminergic tonic inhibition. However,
this effect was rather weak, suggesting a minor participation of
endogenous histamine in the tonic regulation of ACh release. This
®nding seems to be in contrast with the hypothesis that the robust
decrease in ACh release elicited by H3 antagonists was due to
antagonism of endogenous histamine. Recent evidence demonstrates
that native brain H3 receptors, analogously with other metabotropic
receptors (Lefkowitz et al., 1993), exhibit spontaneous receptor
activity, undergoing an allosteric conformation change capable of
binding G-proteins in the absence of agonists (Morisset et al. 2000).
This activity is accompanied by the occurrence of inverse agonism
exerted by thioperamide and ciproxifan (Morisset et al. 2000).
Clobenpropit also behaves as an inverse agonist (Professor R. Leurs,
Leiden University/Vrije Universiteit, Amsterdam, NL, personal
communication). Therefore, in our experiments, antagonism of H3-
FIG. 10. Bilateral placement of injecting needles in the BLA. The
photomicrograph is representative of an operated brain. Arrows indicate the
end of the bilateral needle tracks. The number indicates the relative position
of the coronal section posterior to bregma according to Paxinos & Watson
(1982).
FIG. 11. Effects of post-training bilateral injections of H3 receptor
antagonists or scopolamine, into the BLA, on contextual fear conditioning.
Rats were injected immediately after training under general anaesthesia
(ketamine, 100 mg/kg i.p.). Each drug was freshly prepared and diluted in
sterile saline to permit the injection of a constant volume of 0.5 mL per side
to each rat. A 300-nM solution of thioperamide corresponded to 44 pg/
0.5 mL, and a 3-mM solution of clobenpropit to 464 pg/0.5 mL. Solutions
were injected over a 1±2-min period and the needle was left in place for
1 min before withdrawing it. Controls were injected with saline. Seventy-
two h after training, freezing was measured during the ®rst 3-min period of
the re-testing. Each bar represents the mean value + SEM of (n) rats.
**P < 0.01 vs. control (ANOVA and Neuman-Keuls's test).
ACh release, fear memory and histamine receptors 1529
ã 2001 Federation of European Neuroscience Societies, European Journal of Neuroscience, 14, 1522±1532
autoreceptor stimulation by endogenous histamine might have only
partially contributed to the potential histamine releasing effect of these
drugs.
This is the ®rst report showing that intra-BLA post-training
injection of scopolamine produced an amnesic effect on fear
conditioning. This indicates a crucial role for the amygdaloid
cholinergic system in the retention of fear memories, and is consistant
with earlier observations of the effects of intra-amygdala infusion of
oxotremorine, alone or associated with atropine, on memory storage
(Dalmaz et al., 1993; Introini-Collison et al., 1996; Vazdarjanova
et al., 1999). Moreover, if cognitive de®cits are related to reduced
availability of ACh in the synaptic cleft (Quirion et al., 1995), and
H3-antagonists reduce ACh release, the same compounds would be
expected to impair cognition. This study substantiates this prediction;
intra-BLA injections of thioperamide and clobenpropit impair
retention for a contextual fear-conditioned response. Post-training
administration of these compounds excludes any in¯uence of the
treatment on acquisition and on other processes that indirectly affect
learning (McGaugh & Izquierdo, 2000), thus suggesting that H3-
antagonists directly modulate memory consolidation processes.
Amnesic animals displayed residual freezing, which is in agreement
with previous observations indicating that Pavlovian fear condition-
ing may be still acquired when either major intra-BLA circuits
(Selden et al., 1991; Vazdarjanova & McGaugh, 1999), or the whole
amygdala (Cahill et al. 2000) have been damaged.
We have reported previously that unoperated rats and ketamine-
anaesthetized rats that received intra-amygdala saline injections
exhibited similar freezing responses to context and acoustic condi-
tioned stimuli (Sacchetti et al., 1999), thus suggesting that post-trial
ketamine anaesthesia and surgical procedures do not in¯uence
negatively avoidance responses by interfering with some late stages
of memory consolidation. In this regard, it is noteworthy that
frequency-speci®c receptive ®eld plasticity induced by pavlovian fear
conditioning was expressed in the brain of ketamine-anaesthetized
animals (Lennartz & Weinberger, 1992). Therefore, it is conceivable
that under our experimental conditions, the amnesic effects caused by
H3 antagonists and scopolamine are independent of ketamine-induced
NMDA blocking action. As H3-antagonists cause amnesia and
reduction of ACh release in the same dose range, it is conceivable
that memory impairment occurs as a consequence of cholinergic tone
inhibition. This ®nding seems dif®cult to reconcile with reported pro-
cognitive effects of thioperamide and clobenpropit in a passive
avoidance response and in object recognition (Meguro et al., 1995;
Giovannini et al., 1999). However, these tests require an intact
cholinergic system (Goldman-Rakic, 1987; Petrides, 1994) in the
cortex. Regional differences in cytoarchitectonic and H3-receptor
location may explain the discrepancy. Functional evidence suggests
that H3 receptors are not localized on cortical cholinergic terminals in
the cortex (Arrang et al., 1995; Blandina et al., 1996; Bacciottini
et al., 1999). Consistently, very low expression of H3 receptor-
encoding mRNA has been detected in the basal forebrain nuclei from
which cholinergic neurons project to the amygdala, the cortex and the
hippocampus (Drutel et al. 2001). If so, the effects of pharmaco-
logical manipulation of H3 receptors on ACh release might be
indirect, and vary according to the regional difference of receptor
arrangements. Indeed, perfusion of the rat cortex with clobenpropit
(Blandina et al., 1996) or thioperamide (Giorgetti et al., 1996) failed
to alter directly spontaneous ACh release.
Consistent with previous ®ndings (Vazdarjanova et al., 1999), this
study stresses the importance of BLA muscarinic receptors for
consolidation of fear memories, and strongly suggests that the
histaminergic system in¯uences this process by regulating cholinergic
activity within the BLA. The same mechanism has been proposed for
other neurotransmitters (Introini-Collison et al., 1996). The hist-
aminergic perikarya are found exclusively in the posterior hypo-
thalamus (Panula et al., 1984; Watanabe et al., 1984), from where
they project to all parts of the CNS, including the BLA (Inagaki et al.,
1988; Panula et al., 1989). The hypothalamus may integrate and
coordinate the behavioural expression of affective states. Thus, it is
conceivable that histaminergic neurons might represent at least one of
the neural bases for hypothalamic in¯uences in the storage of
emotionally based memories, providing the ®ne-tuning to ACh
release necessary to produce the adequate behavioural response.
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